# Xenta Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xenta-biomedical

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.xentabms.com
- Latest round: Series A (Oct 17, 2025)
- Investors on record: 3

## About

Based in Shenzhen, China, Xenta Biomedical is a biotechnology company focused on developing innovative health solutions through advanced biopharmaceuticals and personalized healthcare products that cater to various medical conditions.Founded in 2022 and headquartered in Shenzhen, China, Xenta Biomedical specializes in biotechnology solutions for health enhancement. The company has completed one significant deal, with the most recent transaction occurring in October 2025. The company's operations have been directed towards establishing a strong market presence without any noted changes in its business strategy.Xenta Biomedical specializes in the development and delivery of innovative biotechnology products aimed at enhancing health and wellness. Their core product offerings include advanced biopharmaceuticals and personalized healthcare solutions designed to address specific medical conditions. These products are formulated using proprietary technologies that focus on optimizing therapeutic efficacy and minimizing side effects. Notable applications encompass treatments for chronic diseases such as diabetes and cardiovascular disorders, which are prevalent in many global markets, including North America and Europe. The company serves a diverse clientele that ranges from healthcare providers and hospitals to research institutions, ensuring that their solutions reach both practitioners and end users seeking improved health outcomes.Xenta Biomedical's revenue model is structured around a combination of B2B partnerships and direct-to-consumer sales. Transactions typically involve healthcare organizations purchasing biopharmaceutical products on a subscription basis, allowing for regular supply and continuous access to innovative treatments. Retailers also play a pivotal role in distributing these products to consumers, broadening the market reach. Flagship products, which may include trademarked therapies, are marketed at competitive pricing tiers aimed at ensuring accessibility while maintaining profitability. The company's approach to revenue generation underscores a commitment to cultivating long-term relationships with clients and facilitating ongoing support for their healthcare needs.In October 2025, Xenta Biomedical successfully raised an undisclosed amount of Series A funding led by new investor Chuyao Capital, with participation from AKCOME Fuluona Capital and Guangzhou Weiyin. This financing will support the domestic registration and certification of the company's innovative products, facilitate international market expansion, and enable production investments for products that have obtained CE/FDA certificates. Additionally, the funds will bolster investments in new product research and development, further enhancing the company's testing capabilities. Overall, the company aims to launch new products and expand into new markets, enhancing its global footprint.

## Funding rounds

- Series A, Oct 17, 2025 — AKCOME Fuluona Capital, Chuyao Capital, Guangzhou Weiyin

## Investors

- AKCOME Fuluona Capital (https://capitalatlas.ai/funds/akcome-fuluona-capital) — Series A
- Chuyao Capital (https://capitalatlas.ai/funds/chuyao-capital) — Series A
- Guangzhou Weiyin — Series A